INFU vs. TNDM, EMBC, BBNX, KMTS, AXGN, SIBN, BVS, AVNS, ZIMV, and KIDS
Should you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include Tandem Diabetes Care (TNDM), Embecta (EMBC), Beta Bionics (BBNX), Kestra Medical Technologies (KMTS), AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), and OrthoPediatrics (KIDS). These companies are all part of the "medical equipment" industry.
InfuSystem vs. Its Competitors
Tandem Diabetes Care (NASDAQ:TNDM) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.
Tandem Diabetes Care presently has a consensus price target of $22.44, indicating a potential upside of 78.64%. InfuSystem has a consensus price target of $12.50, indicating a potential upside of 19.96%. Given Tandem Diabetes Care's higher possible upside, research analysts plainly believe Tandem Diabetes Care is more favorable than InfuSystem.
71.1% of InfuSystem shares are owned by institutional investors. 1.9% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 11.4% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Tandem Diabetes Care has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.
InfuSystem has a net margin of 1.12% compared to Tandem Diabetes Care's net margin of -20.51%. InfuSystem's return on equity of 2.78% beat Tandem Diabetes Care's return on equity.
In the previous week, Tandem Diabetes Care had 8 more articles in the media than InfuSystem. MarketBeat recorded 13 mentions for Tandem Diabetes Care and 5 mentions for InfuSystem. Tandem Diabetes Care's average media sentiment score of 1.52 beat InfuSystem's score of 1.46 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
InfuSystem has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Summary
InfuSystem beats Tandem Diabetes Care on 12 of the 17 factors compared between the two stocks.
Get InfuSystem News Delivered to You Automatically
Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InfuSystem Competitors List
Related Companies and Tools
This page (NYSE:INFU) was last updated on 9/9/2025 by MarketBeat.com Staff
